Lululab Selected for Government Project on 'AI Skin-Specialized Remote Medical Technology Development'

[Asia Economy Reporter Lee Gwan-joo] AI beauty and healthcare company Lululab announced on the 26th that it has been finally selected as a business target in the pharmaceutical bio sector of the Patent Office's '2022 IP-R&D Strategy Support Project.'

This project was established to support patent strategies linking intellectual property (IP) and research and development (R&D) to secure core and foundational patents, and to contribute to enhancing national competitiveness by fostering global companies equipped with strong patents.

Selected companies receive deliverables such as patent and paper analysis data related to the project, environmental (market, dispute, etc.) analysis data, core patent summary lists, core patent response strategy reports, intellectual property portfolios, promising R&D task derivation, and analyzed patent databases.

Through this project, Lululab plans to analyze the AI-based skin-specialized telemedicine market and establish R&D directions for the development of skin disease diagnosis and prediction technologies, accelerating its entry into the software (SW) medical device market.

A Lululab representative stated, “Although patent applications related to AI-based skin diagnosis and analysis have rapidly increased since 2016, the number of applications by top applicants is around 10, making it necessary to secure high-quality patents to preoccupy the market. Through this project, Lululab will strengthen technological competitiveness and lay the foundation for innovative growth in new industries by securing core and foundational patents based on the high-quality database obtained.”

This content was produced with the assistance of AI translation services.